Amgen has introduced the “Amgen Partners of Choice” network, uniting its oncology research and development experts with clinical leaders from eight global research centers. This initiative aims to enhance academic collaboration to advance treatment options for patients with unmet needs in oncology. Member institutions include prestigious centers like Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. The network seeks to expedite the development and deployment of innovative cancer treatments through global collaboration and bi-annual scientific summits.
Amgen (NASDAQ:AMGN) today announced the launch of Amgen Partners of Choice, a new network that brings together Amgen’s oncology research and development experts and world-class clinical leaders at eight research centers across the globe. As part of Amgen’s mission to improve care through partnerships across the healthcare ecosystem, the network fosters academic collaboration to advance new treatment options for patients with the greatest unmet needs. The member institutions are:
– Asan Medical Center (Seoul, South Korea)
– Dana-Farber Cancer Institute (Boston)
– West German Cancer Center at University Hospital Essen (Essen, Germany)
– Gustave Roussy (Paris)
– Memorial Sloan Kettering Cancer Center (New York)
– Peter MacCallum Cancer Centre (Melbourne, Australia)
– University Health Network’s Princess Margaret Cancer Centre (Toronto)
– Vall d’Hebron Institute of Oncology (Barcelona, Spain)
“We have a big goal – to make profound differences in changing the standard of cancer care – and we are committed to doing that through collaboration,” said Jean-Charles Soria, M.D., Ph.D., senior vice president, Research and Development at Amgen. “Through Amgen Partners of Choice, we hope to foster earlier, deeper and more frequent academic collaboration to fuel quicker progress for patients facing complex, difficult-to-treat cancers.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The network aims to create multiple collaboration channels globally with the goal of expediting the transition of new, transformational programs to leaders in the clinic. Current Amgen Partners of Choice projects are focused on select disease areas and tumor types including thoracic, gastrointestinal and genitourinary cancers.
“We are entering an extraordinary new era in biotechnology, a moment where both the need for innovation and our ability to innovate are expanding exponentially,” said Professor Fabrice Barlesi, General Director of Gustave Roussy, Paris Saclay Cancer Cluster, Grand Paris. “As a member of Amgen Partners of Choice, we look forward to collaborating closely with Amgen and other member institutions to catalyze the next wave of innovation in the fight against cancer.”
The Amgen Partners of Choice network will convene bi-annual scientific summits where participants will discuss emerging oncology topics and advise on improving clinical trials to foster better outcomes for patients. In June, Amgen hosted the inaugural scientific summit at its headquarters, bringing together Amgen Partners of Choice members for the official launch of the new academic network. During the two-day event, Amgen leaders and network members discussed priority projects and key areas that the network will focus on and how to bring these transformational programs to patients. The next network-wide scientific summit will take place virtually later this year.
Source: BioSpace